Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. boosted its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,960 shares of the biotechnology company’s stock after purchasing an additional 1,087 shares during the period. Ascendis Pharma A/S makes up about 0.6% of Harbor Capital Advisors Inc.’s investment portfolio, making the stock its 25th biggest holding. Harbor Capital Advisors Inc. owned approximately 0.14% of Ascendis Pharma A/S worth $13,398,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ascendis Pharma A/S in the fourth quarter valued at $28,000. Jones Financial Companies Lllp grew its position in Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 197 shares in the last quarter. Blue Trust Inc. raised its holdings in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 328 shares in the last quarter. Quarry LP acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at $96,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 664 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $173.15 on Tuesday. The stock has a 50 day simple moving average of $159.37 and a two-hundred day simple moving average of $147.11. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00. The stock has a market cap of $10.56 billion, a P/E ratio of -24.39 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to analyst estimates of $98.56 million. Sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on ASND shares. Morgan Stanley upgraded shares of Ascendis Pharma A/S from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $180.00 to $250.00 in a research note on Monday, May 5th. Royal Bank of Canada lifted their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, May 2nd. Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, May 2nd. Bank of America boosted their target price on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a “buy” rating in a research note on Monday. Finally, Wedbush lifted their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an “outperform” rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $217.73.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.